Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.
Guy Brusselle, MD, PhD
Advertisement
Guy Brusselle, MD, PhD, of Ghent University Hospital.
Articles by Guy Brusselle, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
ESC 2026 Recap: 5 Practice-Changing Trials to Know
2
Evolocumab Prevents Recurrent Cardiovascular Events Following MI or Stroke
3
Addressing Diagnostic Delays in EoE
4
AIRCULES: Lunsekimig Benefit Scales With Severity, With Njira Lugogo, MD
5